14 - 16 September 2021 | BST (UTC+1)
Advancing Biomarker Analysis Europe:
14 - 16 September 2021 | BST (UTC+1)

Accelerate timelines and reduce risk in drug development through optimised biomarker analysis

Featuring over 30 presentations, the event brings together leading pharma, biotech and academic organisations working in biomarker analysis and assay development, enabling attendees to discuss emerging applications of analytical tools in translational research

Advancing Biomarker Analysis Europe: Online

Benefits to Attending

  • Hear from and meet with the leading figures in biomarker analysis, with over 600 experts working at the forefront of novel multiplexing, cytometry & assay tools and applications attending the virtual event
  • Interact with fellow attendees and speakers through our interactive virtual event platform, designed to offer an immersive conference experience and deliver all the benefits of a live In-Person event at the touch of a button
  • Explore how companies are innovating in biomarker analysis to accelerate timelines and reduce risk in drug development. Presentations consider the latest applications of analytical tools in translational research, with therapeutic case studies in neuroscience, immunology, oncology and infectious disease
  • Learn about developing biomarker assays to support clinical development. Gain insights to reduce attrition rates and optimise clinical development programmes through effective assay development

Agenda at a Glance

Day One | Multiplex Tools For Biomarker Analysis & Translational Research

Day Two | Cytometry Tools & Therapeutic Applications

Day Three | Novel Assays for Clinical Development & Biomarker Validation

Key Speakers

The 2021 event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

Below are some of our confirmed speakers for Advancing Biomarker Analysis Europe: Online

Nathalie Fiaschi

Nathalie Fiaschi

Regeneron

Stephanie Traub UCB

Stephanie Traub

UCB

Vincent Mikol

Vincent Mikol

Sanofi

Bangwen-Xie

Bangwen Xie

GlaxoSmithKline

Steve Hoffmann, FNIH

Steve Hoffmann

FNIH

Delegate Rates

Virtual passes are available in Free & Full levels. Click the comparison chart to see what access is provided at each level.

Event Features​

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual experiences.

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As

Digital Networking Opportunities

Connect directly with other event registrants around the world through direct 1-2-1 chat, video chat and group discussion

Sponsorship

A range of customisable opportunities for lead generation, brand building and global business deals. Whether you’re looking to build business, product launch or increase visibility, we provide a variety of highly effective options to suit budget and requirement.

Virtual Attendance of the event is available in Free* and Full packages

Feature

Free

Full

Access to live presentations and discussions

Join the live agenda throughout the 2 day conference

Access to messaging and networking features on the virtual platform

7 Days

7 Days

Access to all on-demand content

Join the congress as and when you like and catch up on any missed presentations (particularly useful for those with busy schedules or joining from different time zones)

Access to presentations post event and Premium Content Hub

Download event presentations plus additional online content to watch or re-watch at a later date so that you don’t miss out on any key findings.

1 Year

Priority Access to speed networking & discussion sessions

Join targeted breakout-rooms and discussions with high level peers

Submit a whitepaper, poster or article into resource centre

*Free passes are only available to industry R&D or academia.